CIAS
BTAI icon

Capital Investment Advisory Services’s BioXcel Therapeutics BTAI Stock Holding History

Capital Investment Advisory Services’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,108
Closed -$22.7K – 985
2024
Q2 		$22.7K Sell
1,108
-6
-0.5% -$201 ﹤0.01% 759
2024
Q1 		$50.3K Hold
1,114
– – 0.01% 655
2023
Q4 		$52.6K Sell
1,114
-10
-0.9% -$556 ﹤0.01% 660
2023
Q3 		$45.5K Buy
1,124
+41
+4% +$4.14K ﹤0.01% 639
2023
Q2 		$115K Hold
1,083
– – 0.01% 524
2023
Q1 		$323K Buy
+1,083
New +$462K 0.04% 347
2022
Q2 		– Sell
-880
Closed -$294K – 827
2022
Q1 		$294K Hold
880
– – 0.03% 390
2021
Q4 		$286K Sell
880
-131
-13% -$56.2K 0.03% 391
2021
Q3 		$491K Sell
1,011
-16
-2% -$7.04K 0.06% 271
2021
Q2 		$477K Sell
1,027
-11
-1% -$6K 0.06% 283
2021
Q1 		$716K Buy
1,038
+50
+5% +$40.2K 0.1% 195
2020
Q4 		$730K Buy
988
+138
+16% +$107K 0.11% 196
2020
Q3 		$590K Buy
850
+19
+2% +$14.3K 0.11% 177
2020
Q2 		$705K Sell
831
-63
-7% -$41.1K 0.14% 138
2020
Q1 		$320K Buy
+894
New +$321K 0.08% 219
2019
Q4 		– Sell
-313
Closed -$35K – 643
2019
Q3 		$35K Hold
313
– – 0.01% 643
2019
Q2 		$53K Buy
+313
New +$53K 0.02% 538

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Capital Investment Advisory Services's BTAI Position: Q3 2024 in Review

Capital Investment Advisory Services sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 1,108 shares — an estimated $22.7K sold.

Capital Investment Advisory Services first reported a position in BTAI in Q2 2019 and held it in 17 quarters. The position peaked at $730K in Q4 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Capital Investment Advisory Services reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Capital Investment Advisory Services sold 1,108 BioXcel Therapeutics shares in Q3 2024, an estimated $22.7K.
  • Capital Investment Advisory Services first reported a position in BioXcel Therapeutics in Q2 2019 and held it in 17 quarters.
  • Capital Investment Advisory Services's BioXcel Therapeutics position peaked at $730K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Capital Investment Advisory Services's 13F filing for Q3 2024, filed 30 Oct 2024.